TN-301 is under clinical development by Tenaya Therapeutics and currently in Phase I for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase I drugs for Diastolic Heart Failure (HFpEF) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TN-301 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TN-301 overview
TN-301 (TYA-11631) is under development for the treatment of heart failure (HF) with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is administered by oral route. The therapeutic candidate acts by inhibiting histone deacetylase 6 (HDAC6).
Tenaya Therapeutics overview
Tenaya Therapeutics is a biopharmaceutical company. It develops novel therapies for the treatment of heart diseases. The company develops treatments through its product platforms that include cellular regeneration, gene therapy and precision medicine. Its cellular regeneration platform uses novel adeno-associated virus (AAV) vectors to deliver proprietary transcription factors that can drive in vivo reprogramming of resident cardiac fibroblasts into cardiomyocytes. The company’s platform uses isogenic iPSC-derived cardiomyocytes as human disease models to identify and validate new heart failure targets for therapeutic compounds. It develops treatments for indications such as myocardial infarction (MI), cardiomyopathies and for disorders involving cardiac fibrosis and cardiomyocyte loss. Tenaya Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of TN-301’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
